Inactive Instrument

Oculus Innovative Sciences, Inc. Share Price Nasdaq

Equities

US67575P2074

Pharmaceuticals

End-of-day quote Nasdaq
- USD - Intraday chart for Oculus Innovative Sciences, Inc.
Sales 2025 * 16.98M 1.31B Sales 2026 * 21.3M 1.64B Capitalization 8.11M 624M
Net income 2025 * -3M -231M Net income 2026 * -1M -76.88M EV / Sales 2025 * 0.48 x
Net cash position 2025 * - 0 Net cash position 2026 * - 0 EV / Sales 2026 * 0.38 x
P/E ratio 2025 *
-2.13 x
P/E ratio 2026 *
-4.74 x
Employees -
Yield 2025 *
-
Yield 2026 *
-
Free-Float 97.88%
More Fundamentals * Assessed data
Sonoma Pharmaceuticals, Inc. Announces New Distributor in Ukraine CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference CI
Sector Update: Health Care Stocks Ease in Late Afternoon MT
Sector Update: Health Care MT
Top MIdday Decliners MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected MT
Ladenburg Thalmann Initiates Coverage on Sonoma Pharmaceuticals at Buy, $3.25 Price Target MT
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced CI
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 57 26/09/19
Director of Finance/CFO 72 31/12/01
Director of Finance/CFO 56 07/09/20
Members of the board TitleAgeSince
Chief Executive Officer 57 26/09/19
Director/Board Member 79 19/04/07
Director/Board Member 64 18/09/18
More insiders
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
Calendar
More about the company